Ultragenyx Pharmaceutical (RARE)
(Delayed Data from NSDQ)
$44.86 USD
-0.20 (-0.44%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $44.83 -0.03 (-0.07%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RARE 44.86 -0.20(-0.44%)
Will RARE be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for RARE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RARE
Ultragenyx (RARE) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Ionis (IONS) Up 6% on Detailed Data From Angelman Drug Study
RARE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans
Ultragenyx (RARE) to Seek Accelerated Nod for Rare Disease Drug
Ultragenyx (RARE) Moves 7.8% Higher: Will This Strength Last?
Other News for RARE
Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update
Leerink upgrades Ionis to outperform, cites Angelman drug
Ultragenyx to present GTX-102 Angelman syndrome program update
Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium
Ultragenyx Pharmaceutical (RARE) Gets a Buy from Evercore ISI